We have already reported that MDM2 inhibitor has protective effects in acute ischemic kidney injury 12 and crescentic glomerulonephritis 13 in vivo and that the efficacy of MDM2 inhibitor is associated with NFκB inhibition, but not that of p53 signaling. Here, TP53 is linked to crescentic glomerulonephritis.